Gapping up
News:
- ATNM +27.8% (Actinum Pharma and Immedica to commercialize Iomab-B (131I apamistamab) in Europe the Middle East and North Africa)
- AGLE +17.7% (presents additional data from PEACE phase 3 study of Pegzilarginase; submits BLA to FDA for Pegzilarginase)
- SPNE +5% (announces full commercial launch of Reef TA Interbody System)
- GDYN +5% (expands in Europe ceases operations in Russia)
- APAM +4.7% (reports March AUM)
- VTGN +3.8% (VistaGen and AffaMed Complete Key Regulatory Submissions for PALISADE Global Phase 3 Clinical Trial for PH94B)
- CVAC +1.6% (CureVac and GSK Enter into pandemic preparedness contract with German Government)
- GROY +1.2% (provides update on Elemental offer)
- EWCZ +1.1% (declares special dividend of $3.30 per share)
- TAK +0.9% (Phase 3 SHP643-301 study (NCT04070326) evaluating the safety profile and pharmacokinetics of TAKHZYRO in patients 2 to <12 years of age met its objectives)
Analyst comments:
- CRWD +3.6% (upgraded to Buy from Neutral at Goldman)
- CAH +2.6% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- DPZ +0.9% (upgraded to Buy from Neutral at Citigroup)